Fig. 3: Dynamic BH3 profiling and combination treatment of 1889c and MP57 cells with carfilzomib, AZD5991, navitoclax and sunitinib.
From: Proteasome inhibition as a potential therapeutic target in thymic cancer
A Dynamic BH3 profiling showed a significant increase in apoptotic priming for MCL-1 after 6 hours of carfilzomib (12.5 nM) treatment in 1889c, B but not in MP57 cells. C, D Cell viability of 1889c and MP57 after 72 hours treatment with AZD5991 (500 nM), navitoclax (500 nM), carfilzomib (12.5 nM), and combined treatment with carfilzomib plus AZD5991 or navitoclax (p < 0.0001 compared to carfilzomib alone). E Combined treatment of 1889c and (F) MP57 cells with 12.5 nM carfilzomib and increasing concentrations (2–10µM) of sunitinib for 48 hours. Significant synergistic effects required high doses (2 µM) of sunitinib (p < 0.01).
